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Introduction: Greater understanding of molecular pathways impor-
tant in cell growth and proliferation of thoracic malignancies,
particularly non-small cell lung cancer (NSCLC), has resulted in
intense clinical and translational research. There is now considerable
interest in personalizing treatment based on an understanding of
tumor histology and molecular abnormalities. However, there is a
multiplicity of data, often with discordant results resulting in con-
fusion and uncertainty among clinicians.
Methods: We conducted a systematic review and a consensus
meeting of Canadian lung cancer oncologists and pathologists to
make recommendations on the use of biomarkers in NSCLC.
PubMed covering 2005 to March 2010 was searched using MESH
terms for NSCLC and randomized trials, plus text words for the
biomarkers of interest. Conference proceedings from 2005 to 2009
ASCO, ESMO, IASLC, and USCAP were also searched. The
articles were reviewed by pairs of oncologists and pathologists to
determine eligibility for inclusion.
Results: Ten oncologists and pathologists reviewed and summa-
rized the literature at a meeting attended by 37 individuals. Draft
recommendations were formulated and agreed upon by consensus
process. There is some evidence that histology is prognostic for
survival. There is evidence from multiple randomized clinical trials
to recommend the following: histologic subtype is predictive of
treatment efficacy and for some agents toxicity. Immunohistochem-
istry testing should be performed on NSCLC specimens that cannot
be classified accurately with conventional H&E staining. As EGFR
mutations are predictive of benefit from tyrosine kinase inhibitors,
diagnostic NSCLC samples should be routinely tested for EGFR-
activating mutations. Clinical data on K-RAS mutations are incon-
sistent, therefore testing is not recommended. There is insufficient
evidence to recommend other biomarker testing. No biomarkers to
date reliably predict improved efficacy for anti-VEGF therapy.
Routine assessment for EML4/ALK mutations is not recommended
at present, although emerging data suggest that it may become
valuable in the near future.
Conclusions: Assessment of NSCLC biomarkers is becoming in-
creasingly important. Therefore, adequate diagnostic material must
be obtained for accurate histologic subtyping and relevant molecular
biology assays.
Key Words: Non-small cell lung cancer, Systematic review,
Biomarker.
(J Thorac Oncol. 2011;6: 1379–1391)
Significant advances in the treatment of non-small cell lungcancer (NSCLC) have been made over the past 25 years
(Figure 1). We have evolved from a state of relative nihilism
about the role of systemic therapy for this malignancy to one
in which there is high quality evidence supporting the use of
first,1–3 second,4–6 and even third-line systemic therapies.7
The trials have not only demonstrated improved survival of
patients with advanced NSCLC but also shown improve-
ments in patient symptoms and quality of life.8 Until recently,
it was assumed that these treatments should be applied
irrespective of histologic subtype of NSCLC.
Nevertheless, the improved outcomes from current
treatment options are modest. More recently, research has
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focused on understanding the molecular abnormalities asso-
ciated with NSCLC cell growth and proliferation and their
impact on response to treatment and survival. These may
result in altered function or overexpression of a number of
cell surface receptors and downstream intracellular pathways
which are thought to be clinically important determinants of
cell growth. However, it is important to separate those mark-
ers which inform the natural history of the disease (prognostic
marker) from those markers which identify a subgroup of
patients likely to benefit more or less from a specific treat-
ment (predictive marker).
Common molecular abnormalities in NSCLC involve
the epidermal growth factor receptor (EGFR), the KRAS
oncogene, and the vascular endothelial growth factor and its
receptors (VEGFR). Activating mutations of EGFR,9,10 up-
regulation through increased gene copy number, or protein
overexpression occur frequently.11,12 KRAS mutations occur
in 20 to 25% of patients13 and have been reported to affect
prognosis negatively.14 In addition, less common genetic
mutations, such as EML4/ALK translocations, may also be
clinically important in NSCLC pathogenesis.15 Other molec-
ular abnormalities involving genes such as excision repair
cross-complement 1 (ERCC1), p53, BRCA, and -tubulin
may also be important predictors of sensitivity to systemic
treatment options.
The availability of newer treatment options targeting
specific molecular abnormalities in NSCLC has resulted in
considerable biomarker research aimed at identifying predic-
tive biomarkers of efficacy. As a result of these changes, there
has been a shift from a treatment algorithm applicable to the
majority of patients to a more complicated situation in which
treatment decisions are influenced by a variety of factors
including histologic subtype and molecular phenotype. The
rapid expansion of knowledge has resulted in considerable
uncertainty about treatment choices in NSCLC. Furthermore,
biomarker research findings are variable between studies, and
variable technologies may be difficult to implement or stan-
dardize in the diagnostics laboratory.
Molecular abnormalities may be measured using pro-
tein expression through immunohistochemistry (IHC), gene
expression or copy number using fluorescence in situ hybrid-
ization (FISH) or quantitative polymerase chain reaction
(PCR), or gene mutations using direct sequencing or PCR
techniques. Questions also exist about the appropriate cut
point to distinguish between “positive” and “negative” test
results. Therefore, confusion and uncertainty exist among
clinicians with regard to what biomarkers to routinely incor-
porate into treatment algorithms for patients with NSCLC.
There is a need to provide guidance in this area. This article
reports the results of a systematic review and recommenda-
tions from a consensus meeting of Canadian oncologists and
pathologists involved in the diagnosis and treatment of lung
cancer.
MATERIALS AND METHODS
A representative sample of 37 medical oncologists and
pathologists from across Canada specializing in thoracic
oncology participated in this consensus meeting. The specific
objectives were the following:
Y To review the literature and make recommendations
concerning the prognostic or predictive value of histo-
logic classification of NSCLC.
Y To review the literature and make recommendations
concerning the prognostic and predictive value of mo-
lecular biomarkers in NSCLC.
Literature Search
A literature search from 2005 to March 2010 was
conducted using PubMed and the following search terms:
“nonsmall cell lung cancer/drug therapy” and “randomized”
or “randomised” or “randomly” or “trial” or “trials” or
“study,” plus text words for specific biomarkers. A second
search was conducted to identify articles concerning histol-
ogy using the following terms: “nonsmall cell lung cancer”
and “subtyping” or “subtype” or “histologic” or “classifica-
tion” or “classifying.” Conference proceedings for American
Society of Clinical Oncology (ASCO), European Society of
Medical Oncology (ESMO), and the International Society for
the Study of Lung Cancer (IASLC) World Lung Congresses
were searched from 2005 to 2009.
Study Selection Criteria
Articles eligible for inclusion included full-text articles
and abstracts of randomized clinical trials involving patients
with NSCLC, in which data on prognostic and predictive
impact of histology or biomarker evaluation were reported.
Single-arm phase II trials were only included if there were no
data from randomized trials. Only studies published in Eng-
lish were considered. Outcomes of interest included objective
response rate (ORR), time to progression (TTP), progression-
free survival (PFS), and overall survival (OS). A total of 5439
articles were identified, and 89 articles were included in this
systematic review.
Consensus Process
This is a Canadian consensus developed after a system-
atic review and interdisciplinary evaluation. The articles were
reviewed by five pairs of oncologists and pathologists to
determine studies for inclusion. Data were summarized and
presented at the consensus meeting. Draft recommendations
were formulated at this meeting and agreed upon by consen-
1995 Meta-analysis shows first-line chemotherapy improves survival96
2000 Docetaxel shown to improve survival in two randomized phase III 
trials4, 6
2004 Pemetrexed shown to be non inferior to docetaxel5
2005 Erlotinib shown to improve survival in second and third-line setting5, 7
2006 Bevacizumab + chemo improves survival74
2007 Gefitinib shown to be non inferior to docetaxel22
2009 Gefitinib shown to improve PFS compared with first-line chemo in 
EGFR mutation positive patients60
FIGURE 1. Time line for major advances in the treatment
of non-small cell lung cancer.
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sus. The consensus recommendations were sent to all meeting
attendees for review and approval. The final manuscript was
also sent to meeting attendees for review before submission.
RESULTS
1a: In Patients with NSCLC, is There Sufficient
Evidence to Recommend That Histologic
Subtype Should Influence the Choice of
Systemic Therapy?
Seven trials (n  5408) provide information about the
prognostic and predictive value of histology for patients with
NSCLC (Table 1).7,16–21 Several, but not all, trials show
worse OS for patients with squamous cell histology, suggest-
ing that this subtype is a negative prognostic factor.20,22,23
There is consistent information from three randomized
trials that histology is predictive of benefit from pem-
etrexed.5,17,20,21 A retrospective analysis of the JMEI trial of
second-line pemetrexed versus docetaxel demonstrated that
patients with nonsquamous histology treated with pemetrexed
had significantly longer survival (9.3 versus 8.0 months, HR
0.82 versus 1.40, interaction test [int] p 0.04).20,23 That trial
mostly showed that squamous patients treated with pem-
etrexed had an inferior outcome. Similar results were dem-
onstrated in the JMDB first-line trial comparing cisplatin and
pemetrexed versus cisplatin and gemcitabine.21 Survival was
significantly better in patients with nonsquamous histology
who were treated with cisplatin plus pemetrexed (11.8 versus
10.4 months, HR 0.84 versus 1.23, int p  0.002). However,
survival favored the combination of cisplatin plus gemcit-
abine among patients with squamous cell histology (OS 10.8
versus 9.4 months, p  0.05). The same observation was
observed in the JMEN trial of maintenance pemetrexed.17
The improvement in PFS from maintenance pemetrexed was
observed in patients with nonsquamous histology (PFS, HR
0.44, 95% CI, 0.36–0.55; OS, HR 0.70, 95% CI, 0.56–0.88;
p  0.002). A significant treatment-by-histology interaction
with both PFS (p  0.036) and OS (p  0.033) was noted. A
treatment-by-interaction effect for histology was not ob-
served in one other trial comparing carboplatin with either
pemetrexed or gemcitabine, although the primary outcome of
this trial was quality of life.24
A differential effect of treatment according to histology
has also been observed in trials of some molecularly targeted
agents. In both the BR.21 trial of erlotinib versus best
supportive care7 and the ISEL trial of gefitinib versus best
supportive care,25 a higher ORR was observed in patients
with adenocarcinoma (14% versus 4%, p  0.001, 12%
versus 5%). However, in BR.21, there was no significant
interaction according to histology for OS according to histol-
ogy (HR 0.8 versus 0.7, int p  0.05). Similarly, an analysis
of the FLEX trial evaluating the addition of the EGFR
monoclonal antibody cetuximab to cisplatin and vinorelbine
demonstrated a significant improvement in survival across all
histological subtypes among patients receiving cetuximab.26
Trials evaluating therapies directed against VEGF have
also demonstrated a treatment versus histology effect. A
randomized phase II trial of carboplatin and paclitaxel 
bevacizumab showed an increased risk of fatal hemoptysis in
patients randomized to chemotherapy plus bevacizumab.18
This appeared to be associated with squamous histology and
so patients of this histologic subtype subsequently were
excluded from phase III trials of bevacizumab. Subsequent
analysis of trials of bevacizumab suggests that the risk of
TABLE 1. Summary of Predictive Biomarkers for Histology in NSCLC
Marker Line of Therapy
Patients
(N) Study Clinical Results
Histologic subtype First-line NSCLC 878 E4599 Adenocarcinoma subtype associated with increased PFS (6.6 vs. 5.0 mo, HR
0.65, 0.54–0.78) and OS (14.2 vs 10.3 mo, HR 0.69, 0.58–0.83) with
Bev  CT as compared with CT alone. OS data for remaining histology
subtypes inconclusive.19
First-line NSCLC 99 Phase II Apparent improvement in ORR (50% vs. 20%), TTP (7.1 vs. 4.0 mo, p  0.01)
and median survival (17.8 vs. 12.2 mo, p  0.57) in nonsquamous histologic
subtype. Squamous subtype associated with pulmonary hemorrhage and
bleeding with Bev treatment.18
Second-, third-line
NSCLC
731 BR.21 Adenocarcinoma subtype associated with significantly higher ORR (14% vs.
4%, p  0.001) to erlotinib but not predictive for OS (HR 0.8 vs 0.7, int
p  0.05).7
NSCLC 741 S9806, S0003,
S9308
Histologic subtype not associated with OS and PFS with antimicrotubule-
platinum therapy.16
Second-line NSCLC 571 JMEI Nonsquamous histology associated with significantly longer PFS (0.82 vs. 1.40,
int p  0.04) and OS for patients treated with pemetrexed versus
docetaxel (HR 0.78 vs. 1.56, int p  0.001).20
First-line NSCLC 1725 JMDB Treatment-by-histology interaction analysis predictive of improved PFS (0.95
vs. 1.36, int p  0.02) and OS (0.84 vs. 1.23, int p  0.002) for patients
with nonsquamous histology with Cis  Pem.21
Maintenance
NSCLC
663 JMEN Significant treatment-by-histology interaction predictive of improved PFS (HR
0.44 vs. 0.69, int p  0.036) and OS (HR 0.70 vs. 1.07, int p  0.033) for
patients with nonsquamous histology with Pem.17
NSCLC, non-small cell lung cancer; CT, chemotherapy; HR, hazard ratio; PFS, progression-free survival; OS, overall survival.
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severe pulmonary hemorrhage was associated with the pres-
ence of baseline cavitation in lung lesions.27 In the ECOG
4599 trial of carboplatin and paclitaxel  bevacizumab, the
largest survival benefit was observed in patients with adeno-
carcinoma histology treated with bevacizumab (14.2 versus
10.3 months, HR 0.69, 95% CI, 0.58–0.83).19 Similar data
are not available from the AVAiL trial of cisplatin and
gemcitabine  bevacizumab.28,29 In addition, differential
outcomes have been observed according to histology. The
ESCAPE trial of carboplatin and paclitaxel  sorafenib
permitted entry of patients with squamous histology and
showed no difference in the incidence of fatal hemoptysis
according to histology.30 However, there was a trend toward
worse OS for patients with squamous carcinoma randomized
to chemotherapy plus sorafenib. In contrast, a phase III trial
of vandetanib, a tyrosine kinase inhibitor (TKI) active against
VEGFR and EGFR, compared with erlotinib, did not show
any increased risk of hemoptysis or a differential effect in any
histologic subgroups.31
1b: In Patients with Newly Diagnosed NSCLC,
What Immunohistochemical Testing Should be
Performed Routinely to Classify All Tumors
Including NSCLC-Not Otherwise Specified into
Specific Histologic Types?
A majority of patients with NSCLC present with unre-
sectable disease and frequently the diagnosis is made on
small biopsies or cytology specimens. Light microscopy and
routine H&E staining may be sufficient to distinguish
NSCLC histologic subtypes in a subset of small biopsies or
cytology specimens, but in some instances, histologic sub-
typing is not possible and a diagnosis of NSCLC-not other-
wise specified (NOS) is applied to cases that cannot be
classified further.
Retrospective studies on resected, cytologic, biopsy,
and tissue microarray specimens have investigated the utility
of histochemical stains including mucicarmin, PAS/PASD,
Alcian blue (AB), and antibodies against p63,32–37 cytokera-
tin (CK 5/6),32,34–36,38,39 high-molecular-weight cytokeratins
(34E12),40,41 thyroid transcription factor-1 (TTF-1),37,39,41
CK7,39–41 and more recently desmocollin-342 and napsin
A43–45 in distinguishing squamous cell carcinoma from ade-
nocarcinoma. Different methodologies, comparison of differ-
ent tests, as well as differences in the antibody clones used, or
the interpretation and scoring systems for individual tests
make comparison of data from these studies difficult.
Two recent publications have investigated using a panel
of IHC markers in small biopsies for greater diagnostic
accuracy.46,47 Loo et al.46 observed that using AB/periodic
acid Schiff for mucin in combination with IHC staining for
p63 and TTF-1 in undifferentiated NSCLC samples was able
to predict the histologic subtype of NSCLC, as diagnosed on
resection specimens and classified on morphology alone in
concordance with the latest World Health Organization Clas-
sification of Lung Cancer (4th edition). Nicholson et al.47
found that markers against cytokeratin 5/6, P63, TTF-1, and
a D-PAS stain for mucin increased the diagnostic ability to
classify NSCLC-NOS tumors into squamous cell carcinoma
or adenocarcinoma.
Consensus Recommendation
There is some evidence that histology is prognostic for
survival. There is strong evidence that histologic subtype is
predictive of treatment efficacy and/or toxicity. Therefore,
every effort to accurately subclassify all NSCLC specimens
should be undertaken and could be performed on H&E-
stained slides based on the tumor morphology. In cases with
equivocal morphologic features, routine stains for mucin
(such as AB/PAS) and IHC stains including TTF-1, p63, and
CK5/6 should be performed and their interpretation stated in
the pathology report. The staining pattern should be used to
favor adenocarcinoma or squamous cell carcinoma or to
report the tumor as NSCLC-NOS in cases with equivocal
staining patterns.
Assessment of biomarkers in patients with NSCLC is
likely to become increasingly important. Therefore, it is
recommended that adequate diagnostic material be obtained
to perform appropriate testing for both histologic subtyping
and biomarker assessment. Wherever possible, it is recom-
mended that a biopsy from a primary (lung) or metastatic site
should be obtained rather than a cytology specimen only. For
cytology specimens, it is strongly recommended that a cell
block be prepared in all cases with sufficient material.
2: In Patients with Newly Diagnosed NSCLC,
Should Diagnostic Material be Evaluated
Routinely for Mutations of the Epidermal
Growth Factor Receptor? Should Such Testing
be Performed in all Patients or in a Subset of
Patients Selected on Pathological and/or
Clinical Characteristics?
EGFR Protein Expression (IHC)
Information is available from six trials (Table 2, n 
2691).11,12,48–51 These trials did not examine the prognostic
value of EGFR protein expression. Clinical data on the utility
of EGFR protein expression as a predictive biomarker have
been inconsistent. An analysis from the BR.217,12 and
ISEL11,25 studies showed that patients with EGFR expression
treated with an EGFR-TKI had a higher ORR than those with
EGFR IHC-negative tumors (BR.21: 11% versus 4%; p 
0.03; ISEL: 8.2% versus 1.5%; p value not reported). How-
ever, a differential survival benefit was not demonstrated in
BR.21 (HR 0.68 versus 0.93, int p 0.05), whereas there was
a qualitative interaction based on EGFR expression in ISEL
that was of borderline significance (HR 0.77 versus 1.57, p
0.049). The SATURN trial of maintenance erlotinib versus
placebo after platinum-based chemotherapy also showed no
significant interaction for survival between EGFR IHC status
and treatment effect (HR 0.69 versus 0.77, int p  0.63).48
In the INTEREST trial comparing gefitinib to do-
cetaxel, no differences in ORR, PFS, or OS were observed
according to EGFR protein expression.49 Similar results were
obtained in an analysis of the BMS099 trial comparing
carboplatin and paclitaxel  cetuximab.52 Demonstrating a
treatment interaction based on biomarker status in trials
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comparing one active treatment to another, or the addition of
a targeted agent to standard chemotherapy, is likely to be
more difficult than in placebo-controlled trials, as the mag-
nitude of any treatment difference is likely to be smaller, and
factors predicting better outcomes from the targeted agent
might also predict better outcomes from chemotherapy.
TABLE 2. Summary of the Predictive Biomarkers for EGFR in NSCLC
EGFR protein
expression
Second-, third-line 325 BR.21 EGFR IHC positivity associated with significantly higher response to Erl (11%
vs. 4%, p  0.03) but not OS (HR 0.68 vs. 0.93, int p  0.05)12
Second-, third-line NSCLC 379 ISEL EGFR IHC positivity associated with significantly better survival with
Gef (HR 0.77 vs. 1.57, int p  0.049)11
First-line NSCLC 365 IPASS EGFR IHC not predictive of improved PFS (HR 0.73 vs. 0.97, int p  0.21)
with Gef50
Second-, third-line NSCLC 380 INTEREST EGFR IHC not predictive of improved ORR, PFS (HR 1.29 vs. 0.90) or
OS (HR 1.0 vs. 1.0, int p  0.87) with Gef49
Maintenance NSCLC 742 SATURN EGFR IHC not predictive of improved PFS (HR 0.69 vs. 0.77, int p  0.63)
with
Erl48
First-line NSCLC 500 TALENT EGFR IHC not predictive of improved OS (HR 1.0 vs. 1.02) with Erl51
EGFR copy
number
Second-, third-line NSCLC 159 BR.21 High EGFR copy number associated with significantly higher response (21%
vs. 55%, p  0.02) and increased OS (HR 0.43 vs. 0.80, int p  0.33) with
Erl55
Second-, third-line NSCLC 370 ISEL High EGFR gene copy number associated with significantly longer median
survival with Gef (HR 0.61 vs. 1.16, int p  0.045)11
First-line NSCLC 406 IPASS High EGFR copy number not predictive of PFS (HR 0.66 vs. 1.24, int p 
0.044) independent of EGFR mutation status (FISH/Mut HR 0.48,
FISH/Mut HR 3.85) with Gef50
Second-, third-line NSCLC 374 INTEREST High EGFR copy number not predictive of improved PFS (HR 0.84 vs. 1.30,
int p  0.112) or OS (HR 1.09 vs. 0.93, int p  0.52) with Gef49
Maintenance NSCLC 488 SATURN FISH not predictive of improved PFS (HR 0.68 vs. 0.81, int p  0.35) with
Erl48
First-line NSCLC 500 TALENT No improvement in ORR or OS with Erl in patients with EGFR gene
amplification51
First-line NSCLC 245 TRIBUTE No improvement in ORR (12% vs. 22%, p  0.05) or OS with Erl in patients
with EGFR gene amplification57
First-line NSCLC 453 INTACT I/II No improvement in OS with Gef in patients with EGFR gene
amplification (HR 2.03 vs. 1.01, p  0.05)53
EGFR mutations Second-, third-line NSCLC 204 BR.21 EGFR mutations predictive of response to Erl (27% vs. 7%, p  0.35) but not
predictive of improved OS (HR 0.55 vs. 0.74, int p  0.47)12,55
Second-, third-line NSCLC 215 ISEL EGFR mutations associated with higher response rates with Gef (37.5% vs.
2.6%); insufficient data for survival analysis11
Maintenance NSCLC 437 SATURN EGFR mutations predictive of improved PFS (HR 0.16 vs. 0.78, int p 
0.001) with Erl but not predictive for OS (HR 0.83 vs. 0.77)48
First-line NSCLC 202 BMS099 EGFR mutations not predictive of improved PFS (HR 1.17 vs. 0.95) or
OS (HR 1.62 vs. 0.91) from cetuximab52
EGFR mutations associated with significantly increased:
First-line NSCLC 437 IPASS ORR and PFS (HR 0.48 vs. 2.85, int p  0.0001) with Gef but not OS (data
not mature)60
First-line NSCLC 309 FIRST-SIGNAL ORR (OR 9.2 vs. 0.32) and PFS (HR 0.61 vs. 1.51) with Gef but not OS (HR
0.82 vs. 1.20, data not mature)61
First-line NSCLC§ 172 WJTOG3405 ORR (62% vs. 32%, p  0.0001) and PFS (HR 0.49, 0.37–0.71) with Gef;
data still immature for OS59
Second-, third-line NSCLC 297 INTEREST PFS (HR 0.16 vs. 1.24) and OR (42% vs. 21%, p  0.04) with Gef but not
predictive for OS (HR 0.83 vs. 1.02, int p  059)49
First-line NSCLC§ 230 NEJ002 ORR (74% vs. 31%, p  0.0001) and PFS (HR 0.30, 0.22–0.41) with Gef but
not OS58
Second-/third-line NSCLC 79 IDEAL I/II Predictive of increased ORR to Gef53
First-line NSCLC 312 INTACT I/II Not predictive of OS with Gef (HR 1.77 vs. 0.91, p  0.05)53
First-line NSCLC 293 TALENT Not predictive of ORR, PFS (HR 0.59 vs. 0.95), or OS (HR 0.95 vs. 1.15)
with Erl51
First-line NSCLC 274 TRIBUTE Predictive of ORR (53% vs. 18%, p  0.01) but not predictive of TTP (12.5
vs. 6.6 mo, p  0.092) or OS with Erl57
NSCLC, non-small cell lung cancer; NR, not reported; Erl, erlotinib; Gef, gefitinib; ORR, overall response rate; PFS, progression-free survival; TTP, time to progression.
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EGFR Copy Number (FISH or qPCR)
There are data on 2994 patients from nine trials assess-
ing EGFR gene copy number (Table 2).11,48–51,53–55 Data
from the BR.21 trial suggest that increased EGFR gene copy
number is associated with a worse OS (HR 1.93, 95% CI,
1.09–3.44, Table 5).55
Conflicting results have been observed regarding the
predictive value of EGFR gene copy number and the efficacy
of EGFR-TKIs or EGFR monoclonal antibodies (Table 2).
No differential improvement in OS was observed in patients
with EGFR amplification assessed by PCR in the TALENT,51
TRIBUTE,54 and INTACT I/II53 trials of platinum-based
chemotherapy  an EGFR-TKI. Similarly, FISH status was
not associated with a significant difference in OS in the
INTEREST trial (HR 1.09 versus 0.93, int p  0.52), al-
though there was a trend toward better PFS in FISH-positive
patients receiving gefitinib (HR 0.84 versus 1.3, p 0.112).49
FISH status was not predictive for survival in the SATURN
trial (HR 0.68 versus 0.81, int p 0.35)48 or the trials evaluating
chemotherapy  cetuximab.52,56 The only trials demonstrating
some predictive value from FISH are trials comparing an EGFR-
TKI to placebo. The second-/third-line trials of gefitinib (HR
0.61 versus 1.16, int p 0.45) or erlotinib (HR 0.43 versus 0.80,
int p 0.33) found a correlation between increased EGFR gene
copy (FISH) and OS.7,11,12,55
EGFR Mutations
Activating mutations of the EGFR gene were first
reported in 2005. Deletions in exon 19 and L858R point
mutations in exon 21 were reported to be associated with
increased sensitivity to treatment with EGFR-TKIs.9,10 Avail-
able data suggest that the incidence of such mutations is
greatest among people of Asian ethnicity, adenocarcinoma,
females, and never smokers.53
The presence of an EGFR activating mutation is gen-
erally associated with improved prognosis (Table 5).49,55,57–60
Data from BR.21 did not show a prognostic effect for EGFR
mutations.55 However, data from both the INTEREST and
TRIBUTE trials demonstrate that the patients with EGFR
mutations have a longer PFS and OS irrespective of the
treatment.49,57 Data from the first-line trials comparing an
EGFR-TKI to platinum-based chemotherapy58–60 all show
survival estimates considerably longer than the expected 8 to
10 months in patients with metastatic NSCLC.3
Fourteen trials (n  3259, Table 2) have examined the
predictive value of activating mutations of the EGFR
gene.11,12,48,49,51,53,55,57–61 Three trials compared an EGFR-
TKI with placebo. In patients previously treated with chemo-
therapy in the BR.21 and ISEL trials,11,12,55 the presence of
EGFR mutations was associated with significantly increased
ORR (BR.21: 27% versus 7%; p 004; ISEL: 37.5% versus
2.6%; p value not reported). However, the BR.21 trial did not
demonstrate significantly improved survival for mutation-
positive patients compared with EGFR wild type (HR 055
versus 074; int p  0.05). Interestingly, biomarker analysis
for the SATURN trial of maintenance erlotinib versus pla-
cebo demonstrated a large benefit in PFS for patients with an
EGFR mutation (HR 0.10, 95% CI, 0.04–0.25; p  0.0001),
but there was no evidence of a greater survival benefit for
EGFR mutation-positive patients (HR 0.83 versus 0.77).62
One potential explanation for this is the effect of crossover
among mutation-positive patients.
In the TALENT, TRIBUTE, IDEAL I/II, and INTACT
I/II trials, the presence of an EGFR mutation was not predic-
tive of improved survival from therapy with erlotinib or
gefitinib.51,53,57 However, trials comparing first-line EGFR-
TKI versus platinum-based chemotherapy have shown a large
benefit in PFS for patients with activating EGFR mutations.
In the IPASS study comparing gefitinib to carboplatin and
paclitaxel, PFS in EGFR mutation positive patients was
significantly longer among patients who received gefitinib
(HR 0.48; 95% CI, 0.36–0.64; p  0.001).60 However, there
was a significant qualitative interaction in PFS for EGFR-
negative patients receiving gefitinib (HR 2.85, 95% CI, 2.05–
3.98; p  0.001). No significant differences in OS were
reported. Similar findings were observed in the First Signal
trial of gefitinib versus cisplatin and gemcitabine (mutation
positive, HR 0.394; 95% CI, 0.22–0.7; p  0.0006, mutation
negative, HR 0.86; 95% CI, 0.45–1.65; p 0.319).61 In trials
limited to EGFR mutation positive patients, substantial im-
provements in PFS have also been observed, although no trial
to date has demonstrated improved OS.58,59 Similarly, the
INTEREST trial of second-line gefitinib versus docetaxel
demonstrated increased ORR and PFS (HR 0.16 versus 1.24)
for EGFR mutation positive patients receiving gefitinib but no
differential effect on OS (HR 0.83 versus 1.02, int p  0.59).49
Unlike results obtained from studies with the EGFR-TKIs,
EGFR mutation status was not found to be a predictive bio-
marker for cetuximab efficacy in the BMS099 or FLEX trials.
Consensus Recommendation
There is sufficient evidence from randomized trials
demonstrating that activating mutations of the epidermal
growth factor receptor are predictive of greater benefit from
treatment with TKIs of the epidermal growth factor receptor
(EGFR-TKIs). It is recommended that diagnostic lung cancer
samples of patients with NSCLC be tested routinely for
activating mutations of the EGFR. Given the available clin-
ical data, this testing should be limited to patients with
advanced NSCLC and nonsquamous histology. Testing
should be completed in a licensed clinical molecular genetics
laboratory. Mutation testing is most relevant to treatment
decisions in the first-line therapy setting. Clinical data for
EGFR protein expression using IHC or gene copy using FISH
testing are inconsistent. Therefore, testing using IHC or FISH
is not recommended routinely.
3: Potential Markers of Chemotherapy
Sensitivity: In patients with Newly Diagnosed
NSCLC, is There a Role for the Routine
Assessment of Molecular Markers Such as
K-RAS, Ki-67, p27, p16, Cyclin-Dependent
Kinases, ERCC1, BRCA, -tubulin III, RRM1, P-53?
K-RAS
Data from four trials on the prognostic effect of K-RAS
are summarized in Table 5.48,55,63,64 These trials show no
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clear effect of K-RAS on OS. However, a 2005 meta-analysis
of 23 trials involving 2631 patients suggests that mutations of
the RAS oncogene are a weak negative prognostic factor (HR
1.41, 95% CI 1.18–1.65).65
Information about the predictive value from eight trials
(n  2442, Table 3) of K-RAS mutations is somewhat
conflicting.48,49,51,52,55–57,63,64 In the BR.10 trial of adjuvant
chemotherapy in completely resected stage IB and II NSCLC,
patients with wild-type K-RAS had a significant improvement
in OS from adjuvant chemotherapy (HR 0.69, 95% CI 0.49–
0.95, p  0.03), whereas patients with K-RAS mutations did
not appear to benefit (HR 0.95, 95% CI 0.53–1.71, p 
0.87).64 However, the p value for treatment interaction was
not significant (int p  0.29). In the E4592 trial of adjuvant
radiation  chemotherapy, K-RAS was not correlated with
PFS or OS.63
There is also a lack of consistent information about the
predictive value of K-RAS mutations for EGFR therapy. In
the TRIBUTE trial, patients with K-RAS mutations who
received chemotherapy plus erlotinib appeared to have the
lowest ORR and the shortest PFS and OS.57 Similarly, data
from the BR.21 trial suggested that the patients with muta-
tions of the K-RAS gene receiving erlotinib had a worse OS
than RAS wild type patients (HR 1.67 versus 0.69), although
a statistical test for treatment interaction was not significant
(int p  0.09).12,55
In contrast, several trials evaluating an EGFR-TKIs
have not shown any differential treatment effect of K-RAS
status. The SATURN trial of maintenance erlotinib demon-
strated improved PFS in patients with both K-RAS mutations
and wild type (HR 0.77 versus 0.70, int p  0.95).48 In the
INTEREST trial comparing gefitinib to docetaxel, K-RAS
mutations appeared predictive of ORR for both gefitinib (0%
versus 9%) and docetaxel (3.7% versus 11.9%).49 However,
K-RAS did not predict either PFS (HR 1.16 versus 1.23) or
OS (HR 0.81 versus 1.03, int p  0.51). RAS status was not
predictive of PFS or OS in either the BMS09952 or FLEX56
trials evaluating the EGFR monoclonal antibody, cetuximab.
Other Potential Markers of Chemosensitivity
A variety of other molecular markers have been
postulated to predict sensitivity to chemotherapy including
RRM1, ERCC1, BRCA, class III -tubulin, p-53, plus
Ki-67, p27, p16, and cyclin-dependent kinases (Table 4).
Most of these analyses either have been done in limited
patient populations or lack validation studies that prevent
firm recommendations.
An analysis of the IALT trial of adjuvant chemotherapy
demonstrated that high ERCC1 expression may be prognostic
for improved OS (Table 5; HR 0.88, 0.71–1.10, p 0.26) and
predictive for lack of benefit from chemotherapy (HR 1.14
versus 0.65, int p  0.009).66 Data from three other random-
ized trials suggests the ERCC1 mRNA did not predict for
ORR or OS.67–69
Data from the BR.10 trial suggested that the high levels
of class III -tubulin were prognostic for worse OS (Table 5;
HR 1.72, 1.02–2.88, p  0.04) and predictive of benefit from
adjuvant chemotherapy (HR 0.64 versus 1.0, int p  0.25).70
However, the results of the LACE Bio meta-analysis found
that -tubulin was not predictive of benefit from adjuvant
chemotherapy.71 Data on other markers such as RRM1,69,72
BRCA,72 p-53,64 Ki-67, p27, p16, and cyclin-dependent ki-
nases73 are all insufficient to make any recommendations
supporting routine assessment.
Consensus Recommendation
Mutations of the KRAS gene are weakly prognostic for
poorer survival in NSCLC patients. Clinical data concerning
the predictive value of KRAS for chemotherapy or EGFR
therapy are inconsistent. Therefore, there is currently insuf-
ficient evidence to recommend testing of KRAS.
There is currently insufficient evidence that testing for
ERCC1, BRCA, -tubulin III, RRM1, and P-53 influences
clinical treatment decisions. Therefore, such testing is cur-
rently not recommended. There are no data to support testing
of Ki-67, p27, p16, and cyclin-dependent kinases.
TABLE 3. Summary of the Predictive Biomarkers for K-RAS in NSCLC
KRAS mutations Adjuvant NSCLC 450 JBR.10 Suggests lack of survival benefit with Adj CT for KRAS mutations (HR 0.69 vs. 0.95, int
p  0.29), but test for statistical interaction negative64
First-line NSCLC 274 TRIBUTE KRAS mutations associated with significantly decreased TTP (1.1 vs. 3.8 mo) and median
survival with Erl  CT (4.4 vs. 13.5 mo, p  0.019)57




206 BR.21 Trend to worse OS in patients with KRAS mutations receiving Erl (HR 1.67 vs. 0.69,
int p  0.09)55
Maintenance
NSCLC




275 INTEREST KRAS mutations not predictive of differential ORR, PFS (HR 1.16 vs. 1.23) and OS (HR
0.81 vs. 1.03, int p  0.51) between Gef and Doc49
First-line NSCLC 379 FLEX KRAS mutations not predictive of differential ORR (37% vs. 37%), PFS (HR 0.84 vs.
0.97), or OS (HR 1.00 vs. 0.96) benefit with Cet  CT vs. CT56
First-line NSCLC 202 BMS099 KRAS mutations not predictive of differential PFS (HR 0.64 vs. 1.07) and OS (HR 0.97
vs. 0.93) benefit with Cet  CT vs. CT52
NSCLC, non-small cell lung cancer; Adj, adjuvant; NR, not reported; Erl, erlotinib; Gef, gefitinib; Car, carboplatin; Cis, cisplatin; CT, chemotherapy; Doc, docetaxel; Gem,
gemcitabine; ORR, overall response rate; Pem, pemetrexed; Tax, taxane; PFS, progression-free survival; TTP, time to progression.
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4: Vascular Endothelial Growth Factor (VEGF).
In Patients with NSCLC Who Are Candidates
for Therapy with an Agent Active Against the
VEGF Pathway, Are There Any Reliable
Biomarkers That Can Be Recommended to Aid
in the Selection of Patients for Anti-VEGF
Therapy?
Two randomized trials (ECOG 4599 and AVAiL) eval-
uated the addition of bevacizumab to platinum-based chemo-
therapy.28,29,74 Both trials demonstrated a higher ORR and
improved PFS. However, only the ECOG 4599 trial demon-
strated improved OS.74 The addition of bevacizumab does
result in additional toxicities. However, attempts to identify
biomarkers to improve patient selection have been explor-
atory and so far unsuccessful.
Biomarker data from the ECOG 4599 trial showed that
regardless of treatment arm, low baseline levels in intracel-
lular adhesion molecule (ICAM) were prognostic for better
OS (p  0.00005) and 1-year survival (65% versus 25%,
Table 5) and predictive of a higher ORR (32% versus 14%,
p  0.02), compared with high ICAM.75 High serum VEGF
levels were predictive of response to chemotherapy plus
bevacizumab but not predictive of improved survival. In the
AVAiL trial, high baseline ICAM, VCAM, FGF, and VEGF
were prognostic for shorter OS compared with lower levels.76
In a comprehensive biomarker study by Hanrahan et
al.,77 the authors explored a set of 35 plasma biomarkers in
NSCLC patients at four time points after antiangiogenic
therapy with (a) the VEGF receptor 2 TKI vandetanib alone,
(b) chemotherapy alone, or (c) a combination of the two, in a
TABLE 4. Summary of the Predictive Biomarkers for Other Markers of Chemosensitivity for NSCLC
p53 mutation Adjuvant NSCLC 445 JBR.10 Suggests lack of survival benefit from Adj. CT in patients with p53 mutations (HR
0.78, 0.46–1.32 vs. 0.67, 0.46–0.98, int p  0.65)64
p53 expression JBR.10 p53 expression associated with improved OS from Adj. CT (HR 0.54 vs. 1.40, int
p  0.02)64
ERCC1 expression Adjuvant NSCLC 761 IALT-Bio High ERCC1 expression (IHC) predictive of lack of survival benefit from Adj. CT
(HR 1.14 vs. 0.65, int p  0.009)66
First-line NSCLC 66 BTOG1 ERCC1 mRNA expression not associated with response to (36% vs. 28%, p 
0.79), or survival (median OS 415 vs 327 d, p  0.81) with first-line platinum-
based CT67
First-line NSCLC 366 ERCC1-based
customized trial
Higher ORR in low ERCC1 mRNA expression (53% vs. 47%) to cisplatin-based
chemotherapy but not predictive of TTP (HR 0.79, 0.61–1.03) or OS (median
OS 10.4 vs. 9.5 mo)68
First-line NSCLC 81 GEPC/98-02 Low ERCC1 mRNA levels trend for longer median survival (13.7 vs. 9.5 mo, p 
0.19) and TTP (8.4 vs. 5.1 mo, p  0.07) with Gem  Cis‡. Longer median
survival associated with low mRNA expression levels of both RRM1 and
ERCC1 treated with Gem  Cis compared with high levels of RRM1 and
ERCC1 (11 vs. 2.7 mo)69
RRM1 expression First-line NSCLC 96 HORG High RRM1 mRNA expression associated with significantly increased risk of
progression and death after first-line Gem  Doc (HR 1.02, 1.01–1.02)72
First-line NSCLC 81 GEPC/98-02 Low RRM1 expression associated with significantly longer TTP (median PFS 8.4
vs. 2.7 mo, p  0.02) and median survival after first-line Gem  Cis (median
OS 13.7 vs. 3.6 mo, p  0.009)69
BRCA1 expression First-line NSCLC 96 HORG High BRCA1 mRNA levels associated with increased probability of response to
first-line Gem  Doc (OR 1.09, 1.02–1.16)72
Tubulin expression Adjuvant NSCLC 1149 LACE-Bio Tubulin IHC positivity not associated with survival from Adj. chemotherapy (HR
1.03 vs. 0.83, int p  0.20)71
Early-stage
NSCLC
412 IFCT-0002 Tubulin IHC negativity significantly associated with PFS (median PFS 31 vs. 60
mo, p  0.014) and (OS 72 vs. 84 mo, p  0.013) with neoadjuvant CT97
P27 expression Adjuvant NSCLC 783 IALT-Bio p27Kip1 IHC negativity associated with significantly longer overall survival from




First-line NSCLC 160 E4599 High baseline plasma VEGF levels significantly associated with ORR (33% vs.
8%, p  0.01) and PFS (median 4.5 vs. 6 mo, p  0.04) from Bev but not
survival75
Low baseline plasma ICAM levels significantly associated with ORR and (HR 1.0
vs. 2.14, int p  0.0001) with CT  Bev75
First-line NSCLC 358 AVAiL Low plasma ICAM1 levels associated with a trend toward improved PFS with
Bev (HR 0.64 vs. 1.04, int p  0.15)76
High plasma bFGF levels associated with a trend toward improved PFS (HR 0.47
vs. 0.74, int p  0.15) and OS (HR 0.52 vs. 1.13, int p  0.15)76
First-line NSCLC 123 Phase II Increase in plasma ICAM1 levels after day 8 of vandetanib treatment significantly
associated with improved PFS77
NSCLC, non-small cell lung cancer; Adj, adjuvant; NR, not reported; VEGF, vascular endothelial growth factor; ICAM, intercellular adhesion molecule; bFGF, basic fibroblast
growth factor; Erl, erlotinib; Gef, gefitinib; Car, carboplatin; Cis, cisplatin; CT, chemotherapy; Doc, docetaxel; Gem, gemcitabine; ORR, overall response rate; Pem, pemetrexed; Tax,
taxane; PFS, progression-free survival; TTP, time to progression.
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randomized, three-arm trial. In this study, only lower levels
of ICAM 1 at day 8 after treatment were found to be
significantly associated with poorer treatment outcome in the
groups of patients who received vandetanib.
Consensus Recommendation
No biomarkers to date reliably predict improved effi-
cacy with VEGF or VEGFR inhibition. Clinical characteris-
tics may be associated with toxicity, based on safety data
from phase II trials. These include predominantly squamous
histology (bevacizumab and other agents, but not all), signif-
icant hemoptysis at baseline, and baseline cavitation in a
pulmonary lesion associated with an airway. Further molec-
ular biomarker evaluation should be incorporated into clinical
trials of these agents.
5. EML4/ALK: In Patients with Newly
Diagnosed NSCLC, Should EML4/ALK
Mutations be Assessed Routinely?
The fusion protein created by the translocation of the
echinoderm microtubule-associated protein-like 4 (EML4)
and the anaplastic lymphoma kinase (ALK) genes defines a
new molecular subset of NSCLC with particular clinicopatho-
logic features. Translocations of the EML4/ALK fusion gene are
thought to represent 1.6 to 6.7% of all NSCLC.78–84 Data would
suggest that the ORR, TTP, and OS are similar among patients
with wild-type and EML4/ALK translocations treated with plat-
inum-based chemotherapy.15 In contrast, patients with ALK
mutations appear unlikely to benefit from therapy with an
EGFR-TKI.
Recent data from a phase I trial demonstrate that the
presence of the rearranged EML4/ALK gene is predictive of a
high response rate to specific inhibitors of the ALK fusion
protein.85,86 Patients with a known translocation of the ALK
gene treated with PF02341066 (crizotinib) demonstrated a
high ORR (53%). Randomized trials of crizotinib compared
with platinum-based chemotherapy or second-line docetaxel
or pemetrexed are ongoing.
To date, no one method of reliably assessing EML4/
ALK rearrangements has been determined. FISH,15,87,88
IHC,15,87 and PCR81,89 techniques have all been assessed.
Additional research is needed to determine the optimal
method of assessment.
Consensus Recommendation
As no specific therapy is approved for ALK-associated
NSCLC, routine assessment for this biomarker cannot be
recommended at this time. Considering the emerging avail-
TABLE 5. Summary of Prognostic Biomarkers in NSCLC
Marker Patients (N) Chemotherapy Study Clinical Results
EGFR copy number 159 Second-, third-line
NSCLC
BR.21 EGFR FISH-positive status prognostic for worse survival (HR 1.93, 1.09–
3.44)55
EGFR mutation status 204 Second-, third-line
NSCLC
BR.21 EGFR mutations not prognostic for survival (p  0.91)55
297 Second-, third-line
NSCLC
INTEREST EGFR mutations associated with improved OS irrespective of treatment with
Gef or CT (14/17 mo vs. 7.6/8 mo)49
274 First-line NSCLC TRIBUTE EGFR mutations associated with significantly better TTP (8 vs 5 mo, p 
0.001), and survival (10 mo vs. unable to calculate, p  0.001)
irrespective of treatment with Erl  CT or CT alone57
KRAS mutations status 445 Adjuvant NSCLC JRB.10 KRAS mutations not prognostic for survival (HR 1.23, 0.76–1.71)64
206 Second-, third-line
NSCLC
BR.21 KRAS mutations not prognostic for survival (p  0.71)55
493 Maintenance NSCLC SATURN KRAS mutations associated with significantly shorter PFS48
184 Adjuvant NSCLC E3590 KRAS mutations not prognostic for survival (median OS 30 vs. 42 mo, p 
0.38)63
p53 expression status 445 Adjuvant NSCLC JBR.10 p53 protein overexpression associated with worse OS (HR 1.89, 1.07–3.34)64
180 Adjuvant NSCLC E3590 p53 expression not prognostic for PFS and survival (1-yr OS 85% vs. 77%,
p  0.93)63
p53 mutation status 445 Adjuvant NSCLC JBR.10 p53 mutations not prognostic for survival (HR 1.15, 0.75–1.77)64
183 Adjuvant NSCLC E3590 p53 mutations not prognostic for PFS and survival (median OS 38 vs. 52
mo, p  0.83)63
ERCC1 expression 761 Adjuvant NSCLC IALT-Bio ERCC1 IHC positivity prognostic for survival (HR 0.88, 0.71–1.10, p 
0.26)66
66 First-line NSCLC BTOG1 Trend towards better survival in patients with high ERCC1 mRNA (HR
0.96, 0.92–1.004)67
Tubulin expression 1149 Adjuvant NSCLC LACE-Bio Tubulin IHC positivity prognostic for worse DFS (1.30, 1.11–1.53) and
overall survival in early NSCLC (HR 1.27, 1.07–1.51)71
Antiangiogenic and
other biomarkers
160 First-line NSCLC E4599 Low baseline ICAM levels prognostic for overall survival (1-yr OS 65% vs.
25%, p  0.00005)75
358 First-line NSCLC AVAiL High baseline levels of VEGF, ICAM-1, VCAM-1, and bFGF associated
with shorter overall survival76
NSCLC, non-small cell lung cancer; CT, chemotherapy; HR, hazard ratio; PFS, progression-free survival; OS, overall survival; TTP, time to progression.
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ability of specific targeted agents for these tumors, further
studies aimed at standardizing assays, specifically comparing
IHC to FISH to detect these cases seem urgently required.
DISCUSSION
The advances in understanding of the molecular abnor-
malities occurring in NSCLC have been met with much
enthusiasm among clinicians involved in the treatment of this
disease. This knowledge has generated a number of biologi-
cal hypotheses about molecularly targeted agents and a cor-
responding large number of clinical trials evaluating such
agents, either alone or in combination with standard systemic
treatments. Many trials have failed to demonstrate improve-
ments in survival and the observed benefits have generally
been modest and have often resulted in additional and fre-
quently unique toxicities. Therefore, there is a strong desire to
be able to select patient subgroups that are more likely to
benefit from these treatments.
To address these concerns, translational research has
become a more important end point for clinical trials in recent
years. However, the percentage of patients in whom tumor
samples were available has varied considerably across clini-
cal trials and there has been inconsistency observed in the
results of such analyses. There is also inconsistency in the
end points evaluated including tumor response rate, TTP, and
OS. As a result, there is often conflicting evidence concerning
the use of biomarkers and a lack of clarity about which
biomarkers should be incorporated into routine practice.
Personalizing treatment approaches in NSCLC has be-
come a frequent theme in international meetings, and a
number of leading experts have put forward treatment algo-
rithms based on a number of factors including histologic
subtype, presence of activating mutations of the EGFR, ALK
translocations, and expression of thymidalate synthase,
ERCC1, or RRM1.90
However, it is clear from this systematic review that
there is inadequate information about many of the molecular
markers that have been proposed in NSCLC. The available
data support the need for more accurate histologic subtyping
of all NSCLC tumor samples when possible, as well as
routine assessment for EGFR mutations. Knowledge in this
area although continues to evolve rapidly. Recent publica-
tions have suggested algorithms to help in the classification of
small tumor samples.91 In addition, a recent publication from
the International Association for the Study of Lung Cancer
(IASLC) proposes a change in the classification of lung
adenocarcinoma.92 Such measures may help to implement
changes in histologic reporting. Since the consensus meeting
was held, impressive response rates obtained with crizotinib
were published and suggest that ALK translocation detection
may soon become an integral part of lung cancer diagnosis.93
Furthermore, data from the LACE Bio meta-analysis pre-
sented at the 2010 ESMO meeting do not support the use of
K-RAS94 or p5395 in selecting patients for adjuvant chemo-
therapy. For the majority of biomarkers, there is thus a need
for prospective validation in clinical trials comparing empiric
treatment selection versus biomarker-driven treatments.
The increasing use of biomarkers also highlights an
issue for healthcare funders, particularly for publicly funded
healthcare systems. There is often a desire to rapidly incor-
porate therapeutic advances into routine clinical practice.
However, when the benefit of a new treatment, such as first
line therapy with gefitinib, is limited to a population defined
by a molecular abnormality, healthcare systems need to
respond to the need for the molecular testing as well as the
therapy itself. Well-structured and standardized laboratories
with adequate quality control programs are necessary to
realize the promise of appropriate patient selection.
With increasing data, biomarker use is likely to assume
even greater importance for treatment decisions in lung can-
cer patients. This change will challenge the current diagnostic
paradigm for NSCLC. Many patients are diagnosed from
cytologic samples or small biopsies, where there may be
inadequate amounts of tumor for such biomarker assess-
ments. There is a strong need to obtain adequate diagnostic
samples. Where possible, biopsy rather than cytologic mate-
rial should be obtained. This will require education not only
of oncologists but also of respirologists, thoracic surgeons,
and pathologists involved in the diagnosis of patients with
lung cancer.
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